This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

Bayer for ProfessionalsYour Resource Portal

Kerendia is indicated for the treatment of chronic kidney disease (Stages 3 and 4 with albuminuria) associated with type 2 diabetes in adult patients.

Kerendia®▼ (finerenone) specialists’ resources

Fidelio- DKD Infographic

A visual overview of the Fidelio-DKD trial which demonstrated how Kerendia delayed CKD progression in adults with CKD associated with T2D vs placebo

Download

Dosing guide for Kerendia

This dosing card provides details on initiating treatment with Kerendia, dose adjustment and monitoring requirements.

Download

CKD & T2D - Practical Guide

Support with optimising the management of patients who have Chronic Kidney Disease (CKD) associated with Type 2 Diabetes (T2D).

Download

Hyperkalaemia management

Practical guide to the management of hyperkalaemia

Download

England and Wales Formulary

This information pack may support you with your formulary application in England or Wales.

Download

Scotland Formulary

This information pack my support you with your formulary application in Scotland.

Download

RP-KER-GB-1105 | January 2025

References
1
Bakris GL et al., N Engl J Med 2020; 383:2219-2229